Total O2 sales triple
CHATSWORTH, Calif. - Sales of Chad Therapeutics Total O2 Delivery system tripled in the third quarter of the company’s fiscal year, and the company expects to gain more traction in the market from a significant, new customer that’s begun an advertising campaign.
The boost from Total O2 sales helped to propel Chad’s third quarter revenues by 23% to $6.4 million. Profits jumped by 21% to $505,000. The company also reports that saleso of its Sage therapeutic device, a conserver that automatically switches between settings for patients at rest and at activity, were slower than expected.
In other news, the company plans to begin testing its initial products for the sleep-disorder market.